Treosulfan Completed Phase 2 Trials for Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Secondary Myelodysplastic Syndromes / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Childhood Acute Lymphoblastic Leukemia in Remission / Recurrent Adult Acute Myeloid Leukemia / Childhood Chronic Myelogenous Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Previously Treated Myelodysplastic Syndromes / Adult Acute Myeloid Leukemia in Remission / Recurrent Childhood Acute Myeloid Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Chronic Myelomonocytic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Childhood Acute Myeloid Leukemia in Remission / Accelerated Phase Chronic Myelogenous Leukemia / Adult Acute Myeloid Leukemia With Del(5q) / Recurrent Adult Acute Lymphoblastic Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / De Novo Myelodysplastic Syndromes / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Childhood Myelodysplastic Syndromes Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00860574Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia